- Home
- ALLO vs MFIC Comparison
ALLO vs MFIC Comparison
Compare ALLO & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | MFIC |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 873.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | MFIC |
|---|---|---|
| Price | $2.17 | $10.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | $8.35 | ★ $11.25 |
| AVG Volume (30 Days) | ★ 6.1M | 652.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | $10.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $9.48 |
| 52 Week High | $4.46 | $13.51 |
Technical Indicators
Market Signals| Indicator | ALLO | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 43.77 |
| Support Level | $2.12 | $10.48 |
| Resistance Level | $2.71 | $11.81 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 57.27 | 32.28 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About MFIC MidCap Financial Investment Corporation
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.